- Home
- Meeting Real-world Challenges in Hypercholesterolaemia Management: Insight from a Pan-European Crowdsourcing Activity
Meeting Real-world Challenges in Hypercholesterolaemia Management: Insight from a Pan-European Crowdsourcing Activity
- Prevention
Available Credit:
- 1.00 European Board for Accreditation in Cardiology (EBAC)
Course Published On:
Course Expiry Date:
Overview
In compliance with ISCP guidelines, all speakers/chair persons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities. This programme is supported by an unrestricted educational grant from Novartis.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Disclosure
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session, ‘Meeting Real-world Challenges in Hypercholesterolaemia Management: Insight from a Pan-European Crowdsourcing Activity’ is accredited by the International Society of Cardiovascular Pharmacotherapy (ISCP) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity.
Instructions to participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Target Audience
This programme is intended to educate:
- General Cardiologists
- Preventative Cardiologists
- Primary Care Physicians
Learning Objectives
The overall programme, 'Meeting Real-world Challenges in Hypercholesterolaemia Management: Insight from a Pan-European Crowdsourcing Activity' endeavours to best address the following learning objectives:
- Discuss the current practice gaps in hypercholesterolaemia management
- Recall best practice for assessing CV risk, defining LDL-C targets and offering patient education
- Stratify patients by CV risk category
- Select cholesterol-lowering therapies according to risk category and LDL-C target
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| Welcome | Welcome and introduction | Lale Tokgozoglu () | |
| Session 1 | Current knowledge and practice gaps in hypercholesterolaemia | Kausik Ray () | |
| Session 2 | Further insight into physician and patient behaviour | Yassir Javaid () | |
| Session 3 | Addressing knowledge gaps in hypercholesterolaemia management | Maciej Banach () | |
| Session 4 | Discussion / Live Q&A | Lale Tokgozoglu () Maciej Banach () Kausik Ray () Yassir Javaid () |
Discussion / Live Q&A
Duration:
Speakers: Lale Tokgozoglu () Maciej Banach () Kausik Ray () Yassir Javaid ()
- 1.00 European Board for Accreditation in Cardiology (EBAC)
Related Courses
- 1.00 EBAC
Published:
Learning objectives
- Recall the components of the ‘ominous octet’ & how they contribute to T2DM development
- Identify underlying facets of clinical inertia in T2DM care
- Describe how early adoption of intensive glycaemic control leads to better outcomes in T2DM
- Recall efficacy & the mode of action of various incretin-based treatments
- Adopt an early, intensive glucose-lowering strategy in appropriate individuals
- Select appropriate incretin treatment & dosing regimens according to patient profiles
- Identify individuals likely to gain cardiovascular benefit from GLP-1RAs
- Select appropriate actions following adverse events from incretin-based treatments
- 1.00 EBAC
Published:
Learning objectives
- Incorporate contemporary imaging for PCI in appropriate patients
- Differentiate between modern imaging techniques based on clinical data
- Recall best practices for image acquisition, interpretation and decision-making
- Interpret image data and make clinical decisions generated from existing case study data
- 1.00 EBAC
Published:
Learning objectives
- Incorporate contemporary imaging for PCI in appropriate patients
- Differentiate between modern imaging techniques based on clinical data
- Recall best practices for image acquisition, interpretation and decision-making
- Interpret image data and make clinical decisions generated from existing case study data
- 1.00 EBAC
Published:
Learning objectives
- Incorporate contemporary imaging for PCI in appropriate patients
- Differentiate between modern imaging techniques based on clinical data
- Recall best practices for image acquisition, interpretation and decision-making
- Interpret image data and make clinical decisions generated from existing case study data
- 1.00 EBAC
Published:
Learning objectives
- Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
- Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
- Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
- Assess the interrelationships linking diabetes, HF and CVD.
- Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
- Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
- 1.00 EBAC
Published:
Learning objectives
- Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
- differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
- apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
- assess the interrelationships linking diabetes, HF and CVD;
- interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.